MEDBOT-B Shares Climb Over 3% on Strong Surgical Robot Sales and Optimistic Overseas Outlook

Stock News09:49

MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS, which expressed optimism about the company's robust overseas sales potential. MEDBOT-B reported that its overseas revenue surged 287% year-on-year last year, with sales of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, MEDBOT-B focuses on middle-income developing regions such as South America, South Asia, and Central and Eastern Europe, where surgical robot penetration rates are currently low, indicating substantial demand. It is projected that by 2034, these regions will have a cumulative need for over 10,000 laparoscopic surgical robot installations. As one of the market pioneers, MEDBOT-B is expected to capture a 25% market share. UBS further noted that MEDBOT-B aims to double its total revenue by 2026 compared to 2025, with the proportion of overseas revenue anticipated to rise from 73% last year to over 80%. This growth is expected to help the company achieve breakeven in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193307972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193307972","market":"other","top_or_hot":-1,"title":"MEDBOT-B Shares Climb Over 3% on Strong Surgical Robot Sales and Optimistic Overseas Outlook","media":"Stock News","content":"<p>MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS, which expressed optimism about the company's robust overseas sales potential. MEDBOT-B reported that its overseas revenue surged 287% year-on-year last year, with sales of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, MEDBOT-B focuses on middle-income developing regions such as South America, South Asia, and Central and Eastern Europe, where surgical robot penetration rates are currently low, indicating substantial demand. It is projected that by 2034, these regions will have a cumulative need for over 10,000 laparoscopic surgical robot installations. As one of the market pioneers, MEDBOT-B is expected to capture a 25% market share. UBS further noted that MEDBOT-B aims to double its total revenue by 2026 compared to 2025, with the proportion of overseas revenue anticipated to rise from 73% last year to over 80%. This growth is expected to help the company achieve breakeven in the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEDBOT-B Shares Climb Over 3% on Strong Surgical Robot Sales and Optimistic Overseas Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEDBOT-B Shares Climb Over 3% on Strong Surgical Robot Sales and Optimistic Overseas Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-14 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS, which expressed optimism about the company's robust overseas sales potential. MEDBOT-B reported that its overseas revenue surged 287% year-on-year last year, with sales of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, MEDBOT-B focuses on middle-income developing regions such as South America, South Asia, and Central and Eastern Europe, where surgical robot penetration rates are currently low, indicating substantial demand. It is projected that by 2034, these regions will have a cumulative need for over 10,000 laparoscopic surgical robot installations. As one of the market pioneers, MEDBOT-B is expected to capture a 25% market share. UBS further noted that MEDBOT-B aims to double its total revenue by 2026 compared to 2025, with the proportion of overseas revenue anticipated to rise from 73% last year to over 80%. This growth is expected to help the company achieve breakeven in the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1617","symbol_name":"AI医疗","start_time":0,"source_url":"","article_id":"1193307972","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193307972","pubTimestamp":1776131390,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1617":"AI医疗","VXUS":"国际股票ETF-Vanguard","02252":"微创机器人-B","BK4588":"碎股","BK1100":"医疗保健设备","BK4585":"ETF&股票定投概念","ROBO":"全球机器人自动化ETF-ROBO"},"translate_title":"由于手术机器人销售强劲和海外前景乐观，MEDBOT-B股价上涨超过3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1,"ROBO":1,"VXUS":1},"content_text":"MEDBOT-B (02252) rose more than 3%, with a gain of 2.87% at the time of writing to HK$28.68, and a turnover of HK$9.9557 million. The positive movement follows a recent research report from UBS, which expressed optimism about the company's robust overseas sales potential. MEDBOT-B reported that its overseas revenue surged 287% year-on-year last year, with sales of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, MEDBOT-B focuses on middle-income developing regions such as South America, South Asia, and Central and Eastern Europe, where surgical robot penetration rates are currently low, indicating substantial demand. It is projected that by 2034, these regions will have a cumulative need for over 10,000 laparoscopic surgical robot installations. As one of the market pioneers, MEDBOT-B is expected to capture a 25% market share. UBS further noted that MEDBOT-B aims to double its total revenue by 2026 compared to 2025, with the proportion of overseas revenue anticipated to rise from 73% last year to over 80%. This growth is expected to help the company achieve breakeven in the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193307972","isCrawlerRequest":true}